OC-140 Hydroxychloroquine as a treatment for crohn's disease: enhancing antibiotic ef

[kiny]

Competing interests P Flanagan: None declared, B Campbell: None declared, J Rhodes consultant for: a member of advisory boards for Atlantic, Procter and Gamble and Falk, Speaker bureau with: Received speaking honoraria from Abbott, Falk, Ferring, Glaxo Smith Kline, Procter and Gamble, Schering Plough, Shire and Wyeth, Conflict with: With the University of Liverpool and Provexis UK, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn's disease plus a patent pending for its use in antibiotic-associated diarrhoea.

OC-140 Hydroxychloroquine as a treatment for crohn's disease: enhancing antibiotic efficacy and macrophage killing of E coli